VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
VCYTVeracyte, Inc.
$53.63$4.3B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksVCYTP/E History

VCYT logoVeracyte, Inc. (VCYT) P/E Ratio History

Fairly Valued

Trading at 65.4x, near 5Y avg of 76.8x · 33th percentile · In line with own history · Data 2024–2026

Current P/E (TTM)
65.4x
-15% vs 5Y avg
5Y Avg P/E
76.8x
Median 83.0x
5Y Percentile
33th
Mid-range
PEG Ratio
N/A
5-Year P/E Range
65.4x
Min29.9xMedian83.0xMax132.0x
TTM EPS$1.08
Price$53.63
Earnings Yield1.53%
EPS Growth (1Y)164.5%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of June 22, 2026, Veracyte, Inc. (VCYT) trades at a price-to-earnings ratio of 65.4x, with a stock price of $53.63 and trailing twelve-month earnings per share of $1.08.

The current P/E is 15% below its 5-year average of 76.8x. Over the past five years, VCYT's P/E has ranged from a low of 29.9x to a high of 132.0x, placing the current valuation at the 33th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, VCYT trades at a 196% premium to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.

Relative to the broader market, VCYT commands a significant premium over the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our VCYT DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

VCYT Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
65.4vs22.1
+196%
Above Sector
vs. S&P 500
65.4vs24.4
+168%
Above Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 165% EPS growth (1Y)

VCYT P/E vs Peers

Diagnostics and Omics Tools peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
ACNB logoACNBACNB Corporation
$592M15.9Lowest1.44Best-3%
PAHC logoPAHCPhibro Animal Health Corporation
$1B26.83.58+1883%Best
ILMN logoILMNIllumina, Inc.
$25B29.77.02+171%
TMO logoTMOThermo Fisher Scientific Inc.
$173B26.212.40+7%
HOLX logoHOLXHologic, Inc.
$17B30.5--25%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

VCYT Historical P/E Data (2024–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2026 Q1-$32.21$1.0829.9x-61%
FY2025 Q4Dec 31 2025$42.10$0.8251.6x-33%
FY2025 Q3-$34.33$0.3891.4x+19%
FY2025 Q2Jun 30 2025$27.03$0.3383.0x+8%
FY2025 Q1Mar 31 2025$29.65$0.4172.7x-5%
FY2024 Q4-$39.60$0.30132.0x+72%

Average P/E for displayed period: 76.8x

Export Data
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

2+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

VCYT — Frequently Asked Questions

Quick answers to the most common questions about buying VCYT stock.

What is VCYT's P/E ratio?

Veracyte, Inc. (VCYT) trailing twelve-month P/E ratio is 65.4x, based on TTM diluted EPS of $1.08. The 5-year average P/E is 76.8x and the historical range spans 29.9x to 132.0x.

Is VCYT stock overvalued or undervalued?

VCYT trades at 65.4x P/E, near its 5-year average of 76.8x. The 33th percentile ranking within the 29.9x–132.0x historical range places valuation within normal bounds.

Is VCYT stock expensive?

VCYT is fairly valued relative to its own history. The current P/E of 65.4x is near the 5-year average of 76.8x (33th percentile of historical range).

What is VCYT's historical P/E range?

Over the past 5 years, VCYT's P/E ratio has ranged from 29.9x to 132.0x, with a median of 83.0x and an average of 76.8x. The current P/E of 65.4x places the stock at the 33th percentile of this range. Full historical data spans 2024–2026.

How does VCYT's P/E compare to the S&P 500?

VCYT trades at 65.4x P/E versus the S&P 500 median of 24.4x. The 168% premium to the market typically reflects higher expected earnings growth or quality.

How does VCYT's valuation compare to Healthcare peers?

Veracyte, Inc. P/E of 65.4x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is VCYT's PEG ratio?

VCYT PEG ratio is N/A, based on a P/E of 65.4x and EPS growth of 164.5%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is VCYT's earnings yield?

VCYT earnings yield is 1.53%, the inverse of its 65.4x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

VCYT P/E Ratio History (2024–2026)

Quarterly valuation multiple from closing price and trailing EPS

Current29.9x
Period Avg76.8x
Range29.9x - 132.0x
Change-77%
6 quartersDec 31, 2024 - Mar 31, 2026